Momentum provides a range of high throughput mass spectrometry screening technologies to identify hits for small molecule inhibitors, degraders, covalent binders, PPI inhibitors, and those targeting RNA, followed by cell based chemoprotoemic assays to further probe signals of future clinical utility. This signaling information allows biopharma researchers to make better decisions when selecting and prioritizing compounds during discovery and preclinical development.
Billerica, MA – Momentum Biotechnologies, formerly known as PureHoney Technologies, is a leading CRO focused on providing mass spectrometry-based native detection technologies for lead discovery and the quantification of difficult targets to biopharmaceutical clients globally. The new name better reflects […]
Billerica, MA (October 22, 2021). PureHoney Technologies (PHT) has moved to a new 20,000 SF headquarters and research facility located at 3 Federal St., Suite 300, Billerica, MA 01821. The facility has been custom-designed to maximize the efficiency of existing operations while providing for future growth. The instrumentation labs include the necessary infrastructure to operate up to 40 mass spectrometers in addition to dedicated sample preparation and BL2 labs.
